Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1373 results for social care

  1. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development Reference number: GID-TA11277 Expected publication date: TBC

  2. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  3. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development Reference number: GID-TA11117 Expected publication date: TBC

  4. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

  5. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued Reference number: GID-TA10933

  6. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  7. Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

    In development Reference number: GID-TA10391 Expected publication date: TBC

  8. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

  9. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....

  10. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  11. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  12. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  13. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

  14. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.